💊 الأدوية من أ إلى ي 🧬 الأهداف 🛠 الأدوات 📚 الأدلة
جميع الأدوية تصنيفات الأدوية المجالات العلاجية الآثار الجانبية
الأدلة المسرد الجدول الزمني
المقارنات مسارات الأدوية عائلات الأدوية
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Tamoxifen

CHEMBL83 Phase 4 معتمد Small molecule
Half-Life
5-7 days
Bioavailability
—
Protein Binding
—
Molecular Weight
371.5 g/mol
LogP
7.1
Phase
4

This medication blocks estrogen receptors in breast tissue and is widely used to treat and reduce the risk of hormone receptor-positive breast cancer in both women and men. It is typically taken as a daily tablet for five to ten years as part of a long-term cancer prevention or treatment plan. Regular gynecologic check-ups are recommended because it can have estrogen-like effects on the uterus.

الوزن الجزيئي

371,5150 g/mol

LogP

7,10

TPSA

12,50 Ų

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Endometriosis Benign Prostatic Hyperplasia Cardiovascular Disease Respiratory Disease Pain Management Non-Small Cell Lung Cancer Rheumatoid Arthritis Osteoporosis Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Schizophrenia Bipolar Disorder Infectious Disease Melanoma Gastroesophageal Reflux Disease Inflammatory Bowel Disease Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Obesity Lymphoma Hypertension Breast Cancer Chronic Pain HIV/AIDS Hepatitis C Prostate Cancer Colorectal Cancer

تصنيفات الأدوية

L — L - Antineoplastic and Immunomodulating Agents

آلية العمل

Selective estrogen receptor modulator (SERM).

Pharmacokinetics (PK)

Half-Life 5-7 days

Pharmacodynamics (PD)

الآلية

Selective estrogen receptor modulator (SERM).

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1

                

                

                
                

                    
InChI

                    
InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-

                

                

                

                    
                    

                        
Molecular Formula

                        
C26H29NO

                    

                    
                    

                        
HBD / HBA

                        
- / 2

                    

                    
                    

                        
الروابط القابلة للدوران

                        
8

                    

                    
                    
                    

                        
الذرات الثقيلة

                        
28

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            PPARG (Peroxisome Proliferator-Activated Receptor Gamma)
                            Antagonist
                        

                        
                        Primary Target
                        
                    

                    
                    

                        

                            SIGMAR1 (Sigma-1 Receptor)
                            Antagonist
                        

                        
                    

                    
                    

                        

                            CYP2D6 (Cytochrome P450 2D6)
                            Substrate
                        

                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Major


                            
                                Tamoxifen + Warfarin
                            
                        

                        
                        
Tamoxifen dramatically increases warfarin anticoagulation, causing large INR elevations and a substantially elevated risk of serious bleeding.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
الأسئلة الشائعة

                

                    
                    

                        
                        

                            
This medication blocks estrogen receptors in breast tissue and is widely used to treat and reduce the risk of hormone receptor-positive breast cancer in both women and men. It is typically taken as a daily tablet for five to ten years as part of a long-term cancer prevention or treatment plan. Regular gynecologic check-ups are recommended because it can have estrogen-like effects on the uterus.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Selective estrogen receptor modulator (SERM).

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Tamoxifen: Half-life: 5-7 days.

                        

                    

                    

                    

                        
                        

                            
Yes, Tamoxifen is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            
            

                
                
                    ADME Journey →
                
                
                
            

            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Methotrexate
                            Small molecule
                        
                        
                        
                            Cyclosporine
                            Protein
                        
                        
                        
                            Tacrolimus
                            Small molecule
                        
                        
                        
                            Adalimumab
                            Antibody
                        
                        
                    

                

                

                
                
                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL83.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 2733526.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
إخلاء المسؤولية الطبية

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.